Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309639 | 0.82 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2ERN1TP53 | |
| SCHEMBL1308701 | 0.77 | TUBB4A (0.37) | MEN1KMT2ASMN1; SMN2ERN1TP53 | |
| SCHEMBL11634342 | 0.75 | MEN1 (0.66) | MEN1KMT2ASMN1; SMN2ERN1TP53 | |
| SCHEMBL30943709 | 0.74 | ADRA2A (0.57) | MEN1KMT2AMAPK1CNR2TSHR | |
| SCHEMBL22910008 | 0.74 | CNR2 (0.47) | MEN1KMT2ACNR2ALDH1A1MAPT | |
| SCHEMBL8806213 | 0.74 | ADRA2A (0.57) | MEN1KMT2AMAPK1CNR2TSHR | |
| SCHEMBL477540 | 0.73 | IDO1 (0.55) | MEN1KMT2ASMN1; SMN2TP53CNR2 | |
| SCHEMBL30986735 | 0.73 | IDO1 (0.55) | MEN1KMT2ASMN1; SMN2TP53CNR2 | |
| SCHEMBL3862578 | 0.73 | IDO1 (0.55) | MEN1KMT2ASMN1; SMN2TP53CNR2 | |
| SCHEMBL30273872 | 0.73 | IDO1 (0.55) | MEN1KMT2ASMN1; SMN2TP53CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066632-B1 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE | CHONG KUN DANG PHARM CORP (KR) | 2013-09-04 | — | — | EP | disclosed |
| US-8053439-B2 | Benzophenone derivatives useful for inhibiting formation of microtubule | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2011-11-08 | — | — | US | disclosed |
| US-20090275575-A1 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2009-11-05 | — | — | US | disclosed |
| EP-2066632-A1 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE | Chong Kun Dang Pharmaceutical Corp. (KR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008038955-A1 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275575-A1 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE | TUBB1, TUBA1C, TUBB6 | MEN1 3206/4885KMT2A 3246/4885SMN1; SMN2 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.